Cabozantinib represents a treatment option for patients with advanced hepatocellular carcinoma who progress after sorafenib.

Adverse events associated with cabozantinib may be effectively managed with supportive care and dose modifications, thereby allowing patients to continue treatment at the appropriate dose, with minimum interruption.

Studies of cabozantinib in the first-line setting are ongoing; by understanding the safety profile of this drug, clinicians will be able to balance efficacy with tolerability for each patient.